Drugs / HRS-5635
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05808374 | Apr 2023 → May 2024 | chronic hepatitis B virus infection | Fujian Shengdi Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06425341 | Jun 2024 → Aug 2026 overdue | chronic hepatitis B virus infection | Fujian Shengdi Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07606950 | Jun 2026 → Jun 2028 expected | chronic hepatitis B virus infection | Fujian Shengdi Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRS-5635 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05808374 ↗ |
| Route | Subcutaneous | “HRS-5635 Injection low dose administered by subcutaneous injection” NCT06425341 ↗ |